Scholarlink

<p>To study the mechanisms of relapse in <i>KMT2A</i>-rearranged (<i>KMT2A</i>-r) acute lymphoblastic (ALL) and acute myeloid leukemia (AML), we performed whole-genome and exome sequencing of infants and children with relapsed ALL/AML (<i>n</i> = 36), and longitudinal deep-sequencing of 257 samples in 30 patients. Somatic alterations in drug-response genes, most commonly in <i>TP53</i> and <i>IKZF1</i> (64%), were highly enriched in early relapse ALL (79%, 9-36 months after diagnosis), but rare in very early relapse ALL (&lt;9 months, 9%). A marked chemotherapy-exposure signature was detected for mutations in early relapse ALL but not in very early ALL or AML relapse, in line with different mechanisms of relapse. Longitudinal analyses could track residual leukemia cells, clonal drug responses, and the upcoming relapse. These results highlight that <i>KMT2A</i>-r ALL and AML evade therapy differently and provide insights into the mechanisms of relapse in this highly lethal form of pediatric acute leukemia.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The genomic landscape of relapsed infant and childhood KMT2A-rearranged acute leukemia

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月8日

查看全文
  • Louise Ahlgren,
  • Mattias Pilheden,
  • Helena Sturesson,
  • Guangchun Song,
  • Michael P. Walsh,
  • Minjun Yang,
  • Maud Maillard,
  • Huanbin Zhao,
  • Zhongshan Cheng,
  • Varsha Singh,
  • Anders Castor,
  • Cornelis Jan Pronk,
  • Hanne Vibeke Marquart,
  • Birgitte Lausen,
  • Pauline Schneider,
  • Gisela Barbany,
  • Katja Pokrovskaja Tamm,
  • Jonas Abrahamsson,
  • Olli Lohi,
  • Linda Fogelstrand,
  • Pablo Menendez,
  • Rob Pieters,
  • Jinghui Zhang,
  • Karin Lindkvist-Petersson,
  • Jun J. Yang,
  • Tanja A. Gruber,
  • Ronald W. Stam,
  • Jing Ma,
  • Anna K. Hagström-Andersson

摘要

To study the mechanisms of relapse in KMT2A-rearranged (KMT2A-r) acute lymphoblastic (ALL) and acute myeloid leukemia (AML), we performed whole-genome and exome sequencing of infants and children with relapsed ALL/AML (n = 36), and longitudinal deep-sequencing of 257 samples in 30 patients. Somatic alterations in drug-response genes, most commonly in TP53 and IKZF1 (64%), were highly enriched in early relapse ALL (79%, 9-36 months after diagnosis), but rare in very early relapse ALL (<9 months, 9%). A marked chemotherapy-exposure signature was detected for mutations in early relapse ALL but not in very early ALL or AML relapse, in line with different mechanisms of relapse. Longitudinal analyses could track residual leukemia cells, clonal drug responses, and the upcoming relapse. These results highlight that KMT2A-r ALL and AML evade therapy differently and provide insights into the mechanisms of relapse in this highly lethal form of pediatric acute leukemia.